A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer
A phase 3 trial testing MRG002 in bladder & urothelial cancer, now recruiting.
Overview
A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer is a phase 3 interventional study registered as NCT05754853, led by Shanghai Miracogen, and recruiting when checked on 2026-09-11. Official title: An Open-label, Randomised, Multi-centre, Phase III Clinical Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Urothelial Cancer Previously Treated With Platinum-based Chemotherapy and PD-1/PD-L1 Inhibitors. Planned enrolment is 290 participants (estimated). The study started in 2023-04-06 and primary completion is expected in 2025-10. No results have been posted on ClinicalTrials.gov.
Similar pages
not linked directly; found by shared links- TrialA Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC)
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of TAR-200 in Combination With Cetrelimab Versus Concurrent Chemoradiotherapy in Participants With Muscle-invasive Bladder Cancer (MIBC) of the Bladder
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Sasanlimab in People With Non-muscle Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study to Evaluate TAR-210 Versus Intravesical Chemotherapy Treatment in Participants With High Risk Non-Muscle-Invasive Bladder Cancer
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Intravesical SHR-1501 Combination With BCG Versus Investigator-selected Chemotherapy in Subjects With BCG-unresponsive NMIBC
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of SHR-1501 Combination With BCG Versus Placebo Combined With BCG in Subjects With Papillary-Only NMIBC
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Shares Bladder & urothelial cancer and the tag ctgov-ingest.
- TrialA Study of CTX-009 in Combination With Paclitaxel in Adult Patients With Unresectable Advanced, Metastatic or Recurrent Biliary Tract Cancers (COMPANION-002)
Shares Bladder & urothelial cancer and the tag ctgov-ingest.